EMAS travel award

EMAS travel award EMAS will support the travel costs for junior members who wish to attend international meetings and congresses; or, for example, those who wish to visit laboratories for specific short-term activities, such as collaborative research, or in order to learn new techniques. This is subject to them meeting the assessment criteria for these…

JuMP 2019-2021

JuMP 2019-2021 EMAS is delighted to announce the third round of the Junior Mentorship Program (JuMP) for the period 2019-2021. The deadline for mentee applications is Monday, October 28th 2019. You can download the application form here: Application form JuMP 2019 -2021. Following evaluation by the JuMP committee, selected mentees will be paired with mentors. JuMP is planned…

Global Position Statement on testosterone treatment for women

The first Global Position Statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), was published in four leading international medical journals on 2 September 2019: Climacteric, Maturitas, The Journal of Sexual Medicine, and The Journal of Clinical Endocrinology and Metabolism. The statement has been authored by a diverse team of leading experts…

#EMAS2019 in the news

#EMAS2019 in the news Integrating novel scientific insights into clinical application the multidisciplinary international congress was extremely successful and enjoyed by all participants. As part of its menopause week, the BBC filmed speakers on both women’s and men’s health. The clips are below. We look forward to May 2021 when the next congress will be in…

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Collaborative Group on Hormonal Factors in Breast Cancer

30 August 2019 A meta-analysis covering the period January 1992 to January 2018 has been published in the Lancet by the Collaborative Group on Hormonal Factors in Breast Cancer. It has reported on the risk of breast cancer with MHT in relation to the type and timing of therapy. During prospective follow-up, 108 647 postmenopausal women…